BR112015015847A2 - composição farmacêutica sólida ou semi-sólida, forma de dosagem sólida ou semi-sólida, uso de um álcool polialcoxilado e método para aumentar a solubilidade ou a taxa de dissolução de um ingrediente farmacêutico ativo - Google Patents

composição farmacêutica sólida ou semi-sólida, forma de dosagem sólida ou semi-sólida, uso de um álcool polialcoxilado e método para aumentar a solubilidade ou a taxa de dissolução de um ingrediente farmacêutico ativo

Info

Publication number
BR112015015847A2
BR112015015847A2 BR112015015847A BR112015015847A BR112015015847A2 BR 112015015847 A2 BR112015015847 A2 BR 112015015847A2 BR 112015015847 A BR112015015847 A BR 112015015847A BR 112015015847 A BR112015015847 A BR 112015015847A BR 112015015847 A2 BR112015015847 A2 BR 112015015847A2
Authority
BR
Brazil
Prior art keywords
solid
semi
polyalkoxy
active pharmaceutical
alcohol
Prior art date
Application number
BR112015015847A
Other languages
English (en)
Inventor
Keith Harris J
Zhao Jin
L Tulchinsky Michael
Ladika Mladen
H Kalantar Thomas
Original Assignee
Dow Global Technologies Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Global Technologies Llc filed Critical Dow Global Technologies Llc
Publication of BR112015015847A2 publication Critical patent/BR112015015847A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/04—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers only
    • C08G65/06—Cyclic ethers having no atoms other than carbon and hydrogen outside the ring
    • C08G65/16—Cyclic ethers having four or more ring atoms
    • C08G65/20—Tetrahydrofuran
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02—Polyalkylene oxides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

resumo “composição farmacêutica sólida ou semi-sólida, forma de dosagem sólida ou semi-sólida, uso de um álcool polialcoxilado e método para aumentar a solubilidade ou a taxa de dissolução de um ingrediente farmacêutico ativo” a presente invenção refere-se ao uso de álcoois polialcoxilados da fórmula r-o-(ao)-h, sendo que r é um grupo alquila substituído ou não substituído, alquenila, alquinila, arila, aralquila ou um grupo heterocíclico tendo 7 a 25 átomos de carbono, (ao) é uma parcela de polioxialquileno da composição (bo)m(eo)n(do)r com arranjo aleatório ou um arranjo bloco a bloco (“blockwise”) das unidades de oxialquileno constituintes, onde m, n e r representam o número médio de unidades de oxibutileno (bo), unidades de oxietileno (eo) e unidades de oxialquileno derivadas de pelo menos um epóxido selecionado a partir do óxido de estireno e óxidos de alquileno tendo de 5 a 10 átomos de carbono (do) por molécula do álcool polialcoxilado, respectivamente, m sendo um número maior que ou igual a 1, n sendo um número maior que ou igual a 1 e r sendo um número na faixa de 0 a 50 sob a provisão de que (m+n+r) é menor que ou igual a 200 e a proporção n/(m+r) está na faixa de 1 a 20, como excipientes na composição farmacêutica. dito álcool polialcoxilado capacita uma solubilização muito efetiva de ingredientes farmacêuticos ativos pobremente solúveis em meio aquoso. as composições farmacêuticas sólidas ou semi-sólidas compreendendo um ou mais tais como álcool polialcoxilado combinado com pelo menos um ingrediente farmacêutico ativo sendo adicionalmente estáveis em longos períodos sob condições de armazenamento típicas e podem ser facilmente providos em várias formas de dosagens, tais como tabletes e cápsulas preenchidas.
BR112015015847A 2013-03-20 2014-01-13 composição farmacêutica sólida ou semi-sólida, forma de dosagem sólida ou semi-sólida, uso de um álcool polialcoxilado e método para aumentar a solubilidade ou a taxa de dissolução de um ingrediente farmacêutico ativo BR112015015847A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361803478P 2013-03-20 2013-03-20
PCT/US2014/011284 WO2014149160A1 (en) 2013-03-20 2014-01-13 Polyalkoxylated alcohols as excipients for pharmaceutical compositions

Publications (1)

Publication Number Publication Date
BR112015015847A2 true BR112015015847A2 (pt) 2017-07-11

Family

ID=50023898

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015015847A BR112015015847A2 (pt) 2013-03-20 2014-01-13 composição farmacêutica sólida ou semi-sólida, forma de dosagem sólida ou semi-sólida, uso de um álcool polialcoxilado e método para aumentar a solubilidade ou a taxa de dissolução de um ingrediente farmacêutico ativo

Country Status (7)

Country Link
US (1) US9592294B2 (pt)
EP (1) EP2976108B1 (pt)
JP (1) JP6027285B2 (pt)
KR (1) KR101688852B1 (pt)
CN (1) CN105007946B (pt)
BR (1) BR112015015847A2 (pt)
WO (1) WO2014149160A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3169324B1 (en) 2014-07-14 2019-05-08 Orion Biotechnology Canada Ltd. Microbicidal composition comprising an octoxynol and a quinolizidine alkaloid compound or a source thereof
EP3893846A1 (en) * 2018-12-11 2021-10-20 Dow Global Technologies LLC Aqueous solutions of poorly soluble active ingredients using polyalkyoxylated amino alcohols
BR112021008954A2 (pt) * 2018-12-11 2021-08-10 Dow Global Technologies Llc composição, e, método
BR112021009135A2 (pt) 2018-12-13 2021-08-10 Dow Global Technologies Llc formulação de detergente líquido para roupas

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147131A (en) 1995-11-15 2000-11-14 The Dow Chemical Company High internal phase emulsions (HIPEs) and foams made therefrom
DE69904014T2 (de) 1999-02-19 2003-04-30 Warner-Lambert Co., Morris Plains Therapeutisch wässerige Zusammensetzung enthaltend ein Hexahydro-5-pyrimidinamine Derivat und einen polyalkoxylierten Fettalkohol
US6372251B2 (en) 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
DE50003908D1 (de) 2000-08-04 2003-11-06 W Kolb Ag Hedingen Dr Tocopherylalkoxylate, deren Herstellung und Verwendung in kosmetischen und pharmazeutischen Formulierungen
DE10053512A1 (de) 2000-10-27 2002-05-02 Basf Ag Verwendung von Terpenalkohol-Ethoxylaten als Solubilisatoren in kosmetischen oder pharmazeutischen Zubereitungen oder Konzentraten für Lebensmittelzubereitungen
US20020094945A1 (en) * 2000-12-18 2002-07-18 Gross Stephen F. Reaction products of alkoxylated compounds and polyepoxides
EP1401503B1 (en) 2001-06-22 2007-05-09 Pfizer Products Inc. Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug and a solubility-enhancing polymer
CN1280246C (zh) 2002-04-26 2006-10-18 巴斯福股份公司 C10链烷醇烷氧基化物及其应用
JP2006188619A (ja) 2005-01-07 2006-07-20 Ge Toshiba Silicones Co Ltd 水中油型ポリオルガノシロキサンエマルジョン
GB0907003D0 (en) 2009-04-23 2009-06-03 Syngenta Ltd Formulation
JP5647143B2 (ja) * 2009-11-30 2014-12-24 株式会社 資生堂 ポリマーソーム及び製造方法
EP2377556A1 (de) 2010-04-14 2011-10-19 Cognis IP Management GmbH Eine Zusammensetzung

Also Published As

Publication number Publication date
EP2976108A1 (en) 2016-01-27
CN105007946B (zh) 2017-09-29
CN105007946A (zh) 2015-10-28
US9592294B2 (en) 2017-03-14
JP6027285B2 (ja) 2016-11-16
JP2016516027A (ja) 2016-06-02
EP2976108B1 (en) 2018-10-10
WO2014149160A1 (en) 2014-09-25
US20150374823A1 (en) 2015-12-31
KR20150119962A (ko) 2015-10-26
KR101688852B1 (ko) 2016-12-22

Similar Documents

Publication Publication Date Title
BR112015015847A2 (pt) composição farmacêutica sólida ou semi-sólida, forma de dosagem sólida ou semi-sólida, uso de um álcool polialcoxilado e método para aumentar a solubilidade ou a taxa de dissolução de um ingrediente farmacêutico ativo
ES2531646T3 (es) Composiciones de emulsión farmacéuticas con bajo contenido de aceite que comprenden progestágeno
BR112015025172A2 (pt) composição farmacêutica
AR025040A1 (es) Auxiliar detergente acuoso multifase que contiene tensoactivos, procedimiento para su elaboracion y empleo del mismo y de aceites perfumados
BR112017008660A2 (pt) formulação de solução de proteína estável contendo alta concentração de um anticorpo anti-vegf
BR112015017246A8 (pt) composição farmacêutica aquosa, seu uso e seringa
JP2006104221A5 (pt)
RU2016130098A (ru) Композиции в виде геля для местного применения, включающие полимер поликапролактон, и способы повышения эффективности местного применения полезного средства
BRPI0615292A8 (pt) composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada
CO5021207A1 (es) Composiciones surfactantes agroquimicas que contienen agroquimicos de fase dispersada y alcoxilatos de alcohol primario ramificado como adyuvantes y metodo de aplicacion
KR930702014A (ko) 시클로스포린 함유 외용 약제
BR112016002915A2 (pt) formulação agroquímica pulverizável, formulação concentrada, uso de um éster graxo de um poliol c3 a c8, ou oligômero do mesmo, e, métodos para reduzir o desvio de pulverização e para tratamento de vegetação para controlar pestes e/ou fornecer nutrientes
CO5570649A2 (es) Producto antitranspirante en gel liquido de alta eficiencia
PA8542701A1 (es) Composición parenteral reconstituible
AR055115A1 (es) Composiciones antitrnspirantes
CN103202772A (zh) 一种具有稳定液晶结构的膏霜组合物及其制备方法
AR092806A1 (es) Formulacion concentrada liquida que contiene un insecticida de piripiropeno i
BR112012015016B8 (pt) formulação farmacêutica, forma de dosagem farmacêutica entérica e uso de uma formulação
KR20130086941A (ko) 수중유형 유화 조성물 및 그 제조 방법
AR110250A1 (es) Formulación tópica que comprende n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida
JP6754171B2 (ja) 油中水型乳化組成物
AR063111A1 (es) Una formulacion farmaceutica de taxano
JP6371519B2 (ja) 皮膚外用組成物
BR112015028302A2 (pt) formulação de pastilha de nicotina
RU2018119510A (ru) Композиции изотретиноина и их применение и способы

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]